FCF Healthcare & Life Sciences Venture Capital Monitor - Europe - Published in August 2026

• Total Healthcare & Life Sciences funding reached EUR 7,843m (+8% vs. 2025)

• Biotech/Pharma received 35% of the total investment volume (EUR 2,761m), with oncology being the leading indication (30%)

• In August, Vaderis Therapeutics (Switzerland) secured the highest transaction volume with EUR 133m, followed by Kynexis (Netherlands) with EUR 97m and Mironid (United Kingdom) with EUR 40m

• GV (United States) is the most active investor (by deal volume in 2026), followed by Alphabet (United States) and CapitalG (United States)

To read the full report, click here.